After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Ryan Cross

Senior Science Correspondent

A secretive biotech startup developing a new form of gene editing is starting to give curious scientists a peek at its pipeline — without fully divulging how its closely scrutinized technology works.

On Friday, Tessera Therapeutics announced preliminary data from five preclinical programs using its “gene writers” to tweak specific letters or insert entirely new sequences of DNA. The techniques are part of a larger movement in the gene editing field to develop tools that could treat nearly any conceivable genetic disease, and Tessera is one of its top contenders.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Ryan Cross

Senior Science Correspondent

To read Endpoints News become a free subscriber

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Af­ter rais­ing half a bil­lion dol­lars, a se­cre­tive biotech gives an ear­ly look at its gene edit­ing pipeline

Ryan Cross

Senior Science Correspondent

To read Endpoints News become a free subscriber

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape